Toshihiko Doi
About
Toshihiko Doi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Toshihiko Doi has authored 424 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 279 papers in Oncology, 216 papers in Pulmonary and Respiratory Medicine and 100 papers in Surgery. Recurrent topics in Toshihiko Doi's work include Gastric Cancer Management and Outcomes (137 papers), Cancer Immunotherapy and Biomarkers (96 papers) and Colorectal Cancer Treatments and Studies (87 papers). Toshihiko Doi is often cited by papers focused on Gastric Cancer Management and Outcomes (137 papers), Cancer Immunotherapy and Biomarkers (96 papers) and Colorectal Cancer Treatments and Studies (87 papers). Toshihiko Doi collaborates with scholars based in Japan, United States and France. Toshihiko Doi's co-authors include Atsushi Ohtsu, Kohei Shitara, Takashi Kojima, Takayuki Yoshino, Sarina A. Piha‐Paul, Narikazu Boku, Yasutoshi Kuboki, Kenji Tamura, Shunji Takahashi and Kei Muro and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.
In The Last Decade
Toshihiko Doi
414 papers receiving 14.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Toshihiko Doi Japan | 62 | 9.3k | 6.4k | 3.6k | 2.6k | 2.0k | 424 | 14.4k | ||
| Kohei Shitara Japan | 55 | 9.3k 1.0× | 6.9k 1.1× | 3.3k 0.9× | 2.2k 0.9× | 2.3k 1.2× | 504 | 14.2k | ||
| Antoîne Italiano France | 67 | 9.0k 1.0× | 9.2k 1.4× | 2.6k 0.7× | 4.0k 1.5× | 1.7k 0.9× | 618 | 17.5k | ||
| Josef Rüschoff Germany | 51 | 8.9k 1.0× | 6.2k 1.0× | 3.4k 0.9× | 4.1k 1.6× | 712 0.4× | 223 | 15.3k | ||
| Johanna C. Bendell United States | 63 | 9.4k 1.0× | 4.3k 0.7× | 2.0k 0.6× | 5.4k 2.1× | 1.9k 1.0× | 535 | 14.8k | ||
| Jayesh Desai Australia | 45 | 7.7k 0.8× | 4.9k 0.8× | 2.0k 0.6× | 3.5k 1.3× | 1.1k 0.5× | 325 | 13.4k | ||
| Akira Sawaki Japan | 44 | 6.3k 0.7× | 7.4k 1.2× | 4.7k 1.3× | 1.9k 0.7× | 409 0.2× | 150 | 11.8k | ||
| Ho Yeong Lim South Korea | 58 | 6.6k 0.7× | 5.7k 0.9× | 3.6k 1.0× | 3.5k 1.4× | 1.0k 0.5× | 369 | 15.0k | ||
| Laura H. Tang United States | 68 | 9.2k 1.0× | 4.0k 0.6× | 4.6k 1.3× | 2.7k 1.0× | 924 0.5× | 292 | 15.6k | ||
| Zev A. Wainberg United States | 51 | 6.2k 0.7× | 3.2k 0.5× | 2.1k 0.6× | 2.8k 1.1× | 1.3k 0.6× | 343 | 9.8k | ||
| Silvana Pilotti Italy | 68 | 6.6k 0.7× | 5.3k 0.8× | 2.7k 0.7× | 5.1k 2.0× | 946 0.5× | 294 | 16.2k |
Countries citing papers authored by Toshihiko Doi
Since
Specialization
Citations
This map shows the geographic impact of Toshihiko Doi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshihiko Doi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshihiko Doi more than expected).
Fields of papers citing papers by Toshihiko Doi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Toshihiko Doi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshihiko Doi. The network helps show where Toshihiko Doi may publish in the future.
Co-authorship network of co-authors of Toshihiko Doi
This figure shows the co-authorship network connecting the top 25 collaborators of Toshihiko Doi. A scholar is included among the top collaborators of Toshihiko Doi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshihiko Doi. Toshihiko Doi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lin, Chia‐Chi, Giuseppe Curigliano, Armando Santoro, et al.. (2024). Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study. BMJ Open. 14(8). e079132–e079132.
2.
Sun, Jong‐Mu, Antoine Adenis, Peter C. Enzinger, et al.. (2024). LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma. Future Oncology. 20(35). 2709–2721.
3.
Pant, Shubham, Joon Oh Park, Wu‐Chou Su, et al.. (2024). Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.. Journal of Clinical Oncology. 42(16_suppl). 4121–4121.
4.
Babu, Sunil, Shunsuke Kondo, Alexander I. Spira, et al.. (2023). 1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors. Annals of Oncology. 34. S647–S648.
5.
Naito, Yoichi, Yoshito Komatsu, Yukinori Kurokawa, et al.. (2023). 1917MO CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Annals of Oncology. 34. S1031–S1032.
6.
Johnson, Melissa L., Mark M. Awad, Martin Gutierrez, et al.. (2023). OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study. Journal of Thoracic Oncology. 18(11). S54–S55.
7.
Kojima, Takashi, Ken Kato, Hiroki Hara, et al.. (2022). Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303). Esophagus. 19(4). 702–710.
8.
Hamid, Omid, Alberto Chiappori, John A. Thompson, et al.. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 10(10). e005471–e005471.
9.
Curigliano, Giuseppe, Hans Gelderblom, Nicolas Mach, et al.. (2021). Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3620–3629.
10.
Aoki, Hiroyasu, Satoshi Ueha, Shigeyuki Shichino, et al.. (2021). Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. Cancer Immunology Research. 9(6). 624–636.
11.
Harding, James J., Víctor Moreno, Yung‐Jue Bang, et al.. (2021). Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clinical Cancer Research. 27(8). 2168–2178.
12.
Maeda, Yuka, Hisashi Wada, Daisuke Sugiyama, et al.. (2021). Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications. 12(1). 7280–7280.
13.
Doi, Toshihiko, Noboru Yamamoto, Yoichi Naito, et al.. (2021). Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study. Cancer Medicine. 10(19). 6579–6589.
14.
Kang, Yoon‐Koo, Yung‐Jue Bang, Shunsuke Kondo, et al.. (2020). Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. Clinical Cancer Research. 26(13). 3202–3210.
15.
Tsumura, Ryo, Yoshikatsu Koga, Akinobu Hamada, et al.. (2020). Report of the use of patient‐derived xenograft models in the development of anticancer drugs in Japan. Cancer Science. 111(9). 3386–3394.
16.
Doi, Toshihiko, Kei Muro, Hiroshi Ishii, et al.. (2019). A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 25(22). 6614–6622.
17.
Segal, Neil H., Aiwu Ruth He, Toshihiko Doi, et al.. (2018). Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clinical Cancer Research. 24(8). 1816–1823.
18.
Ott, Patrick A., Yung‐Jue Bang, Sarina A. Piha‐Paul, et al.. (2018). T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology. 37(4). 318–327.
19.
Matsubara, Nobuaki, Yoichi Naito, Norio Yamamoto, et al.. (2017). Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases. Annals of Oncology. 28. v274–v274.
20.
Kurose, Koji, Yoshihiro Ohue, Hisashi Wada, et al.. (2015). Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clinical Cancer Research. 21(19). 4327–4336.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kohei Shitara Breakdown of academic impact, for papers by Antoîne Italiano Breakdown of academic impact, for papers by Josef Rüschoff Breakdown of academic impact, for papers by Johanna C. Bendell Breakdown of academic impact, for papers by Jayesh Desai Breakdown of academic impact, for papers by Akira Sawaki Breakdown of academic impact, for papers by Ho Yeong Lim Breakdown of academic impact, for papers by Laura H. Tang Breakdown of academic impact, for papers by Zev A. Wainberg Breakdown of academic impact, for papers by Silvana Pilotti